(secondQuint)TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study.

 The study will consist of 2 parts involving up to 12 healthy male participants.

 In Part 1, up to 6 participants will receive a single 80 mg dose of [14C]-TAK-385 administered as an oral solution.

 In Part 2, up to 6 participants will receive a single oral 80 mg dose of TAK-385 administered as two 40 mg tablets and an 80 1/2g intravenous (into a vein) dose of [14C]-TAK-385 (containing not more than 37.

0kBq [1000 nCi] 14C).

 This single centre study will take place in the United Kingdom.

.

 TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study@highlight

The purpose of this 2 part study is to look at how TAK-385 is taken up, broken down and removed from the body when given as a radiolabelled oral solution (by mouth) or as an oral tablet (by mouth) followed by a radiolabelled intravenous (IV) infusion (into the arm vein).

